This innovative monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – presents remarkable promise in the treatment of critical hemolytic disease (TRALI). Developed by Bio-X, Pritoxaximab functions by https://www.targetmol.com/compound/pritoxaximab